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DObjectives: We propose a simplified anatomic classification for pulmonary emboli that algorithmically differ-
entiates those who might be best treated with surgical pulmonary embolectomy (type A) from those best treated
medically (type B). We hypothesized that patients with type A pulmonary emboli treated with immediate
surgical embolectomy demonstrate superior long-term survival compared with patients with type A pulmonary
emboli treated medically.
Methods: Patients admitted between 2002 and 2008 with a diagnosis of pulmonary emboli made based on com-
puted tomographic angiographic imaging (n ¼ 779) were analyzed. Computed tomographic angiographic im-
ages were reviewed in a blind fashion, and anatomic classification of emboli was made. Patients with central
thrombus, defined by location medial to the lateral mediastinal boundaries (ie, involving the main, primary,
or both branch pulmonary arteries), were classified as having type A pulmonary emboli (n¼ 107), whereas those
with peripheral pulmonary emboli located beyond these boundaries were classified as having type B pulmonary
emboli (n ¼ 672). Four patients with type A pulmonary emboli treated with catheter embolectomy were
excluded from the analysis.
Results: Of the 103 patients with type A pulmonary emboli, 15 (14%) were treated with immediate surgical
pulmonary embolectomy, and 88 (85%) were treated medically. Patients with type A pulmonary emboli treated
surgically had similar 30-day mortality compared with those treated medically (13% vs 17%, P ¼ .532). At
a mean of 24  18 months’ follow-up (range, 1–82 months), survival at 1, 3, and 5 years for patients with
type A pulmonary emboli treated surgically was significantly better than that in the patients with type A pulmo-
nary emboli treated medically (P ¼ .0001).
Conclusions: For patients with type A pulmonary emboli, immediate surgical intervention appears to offer su-
perior midterm survival compared with medical treatment alone. Although the medical and surgical groups were
substantially different and the differences might have affected survival, this simplified classification for pulmo-
nary emboli might help direct optimal treatment strategies. (J Thorac Cardiovasc Surg 2011;142:1423-9)Traditionally, pulmonary emboli (PE) have been treated
medically with anticoagulation, whereas thrombolysis and
surgical embolectomy have been reserved for patients
with massive PE with hemodynamic collapse. As a conse-
quence, surgical mortality rates have been discouraging,
ranging from 16% to 64%.1,2 In the late 1990s, the
Brigham and Women’s group proposed a more liberal
application of surgical embolectomy before hemodynamic
shock, resulting in improved short-term and midterm out-e Department of Cardiac Surgery, Vanderbilt Heart & Vascular Institute,
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The Journal of Thoracic and Carcomes. They attributed their results to earlier correction
of right ventricular (RV) dysfunction and higher avoidance
of long-term RV failure.3
For surgical embolectomy to be successful, the embolus
must be both anatomically accessible and hemodynami-
cally relevant. Removal of clot beyond the third-order pul-
monary artery branches is technically difficult and fraught
with the potential risk of vessel laceration. Moreover, clots
at this level, given alternate tributaries, are less likely to rep-
resent a significant obstruction to flow. Conversely, proxi-
mal clot is more easily removed, larger, and more likely
to present a significant hemodynamic burden to the right
ventricle. Therefore we proposed a simplified anatomic
classification system for PE based on location within the
pulmonary arterial tree, which algorithmically defines those
patients who might benefit from surgical embolectomy ver-
sus those in whom medical treatment is ideal.
Patients with central thrombus, defined by location within
the lateral mediastinal boundaries (involving the main, pri-
mary, or both branch pulmonary arteries) were classified as
having type A PE (Figure 1), whereas those beyond these
boundaries were classified as having type B PE (Figure 2).diovascular Surgery c Volume 142, Number 6 1423
Abbreviations and Acronyms
CI ¼ confidence interval
CPR ¼ cardiopulmonary resuscitation
CT ¼ computed tomography
DVT ¼ deep venous thrombosis
PE ¼ pulmonary emboli
RV ¼ right ventricle
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DWe hypothesized that patients with type A PE treated with
immediate surgical embolectomy would derive faster relief
of RV dysfunction, resulting in superior midterm survival
compared with patients with type A PE treated medically.
This algorithm is meant to be similar to that used to treat
type A and type B aortic dissection. Just as a Stanford
type A dissection reflects a condition best treated surgically,
so also a Vanderbilt type A PE reflects a surgical condition.FIGURE 1. Contrast-enhanced chest computed tomographic scan (axial
section) showinga large saddle embolus in thepulmonaryartery (typeAPE).
MATERIALS AND METHODS
We conducted a single-center, retrospective cohort study. Institutional
review board approval was obtained to review the medical and imaging re-
cords of patients whowere admitted to Vanderbilt University Hospital with
the diagnosis of PE from January 2002 to December 2008. Thosewith com-
puted tomographic (CT) angiographic images (n ¼ 779) were then ana-
lyzed. Each CT angiographic image was then reviewed retrospectively in
a blinded fashion by a board-certified cardiothoracic surgeon, and anatomic
classification of emboli was made. Patients with central thrombus, defined
by location within the lateral mediastinal boundaries (ie, involving the
main, primary, or both branch pulmonary arteries), were classified as having
typeA PE (n¼ 107), whereas thosewith thrombus beyond these boundaries
were classified as having type B PE (n¼ 672). Four patients with type A PE
treated with catheter embolectomy were excluded, leaving 103 patients
with type A PE for analysis. All patients with type B PE were treated med-
ically. Patients considered for surgical intervention underwent echocardio-
graphic analysis to assess RV function. RV dysfunction was defined by an
RV/left ventricular end-diastolic diameter ratio of greater than 1 in the api-
cal 4-chamber view, and supportive evidence included paradoxical RV sep-
tal systolicmotion, loss of inspiratory collapse of the inferior vena cava, and
tricuspid regurgitation jet velocity of greater than 2.8 m/s or greater than
2.5 m/s in the absence of inspiratory collapse of the inferior vena cava.
Treatment Algorithm
Our proposed treatment algorithm for PE is presented in Figure 3. In pa-
tients with suspected PE, aortic dissection, or both, a contrast chest CT scan
will confirm the diagnosis of PE. According to our anatomic classification,
patients with a type A PE (central clot) who present with the classic indi-
cations for surgical intervention (hemodynamic instability with shock or
hypotension, patients with contraindications or inadequate response to
thrombolysis, and those with patent foramen ovale and intracardiac
thrombi) are treated with surgical pulmonary embolectomy. Patients with-
out the classic indications for surgical intervention are further screened
with a 2-dimensional echocardiogram to assess RV function. In the pres-
ence of moderate-to-severe RV dysfunction, even without hemodynamic
instability, our preferred approach is to treat the patients with immediate
surgical pulmonary embolectomy. Patients without RV dysfunction are
treated with medical therapy. Patients with type B PE are always treated
with medical therapy. Thrombolytics are usually reserved for patients
with high-risk PE presenting with cardiogenic shock, persistent arterial hy-1424 The Journal of Thoracic and Cardiovascular Surpotension, or both. Routine use of thrombolysis in non–high-risk patients is
considered in selected patients with intermediate-risk PE (in whom
markers of RV dysfunction and myocardial injury are present).
Surgical Technique
Our approach to surgical embolectomy has been previously described.3
All patients received transesophageal echocardiographic analysis for as-
sessment of right- and left-sided heart function and detection of a patent fo-
ramen ovale or atrial septal defect. Median sternotomy with institution of
cardiopulmonary bypass was performed. Embolectomies were generally
performed on a normothermic beating heart unless cardioplegic arrest
was required for closure of a patent foramen ovale or atrial septal defect.
A longitudinal incision was made in the main pulmonary arterial trunk to-
ward the left pulmonary artery and retracted with a vein retractor. If neces-
sary for further exposure, an additional arteriotomy was performed on the
right pulmonary artery between the aorta and superior vena cava. Throm-
buswas removed under direct visionwith ring forceps and open-tip suction.
No Fogarty catheter clot extraction was done to reduce the possibility of
injury to the pulmonary artery branches. The pulmonary artery was then
closed with 4–0 Prolene sutures, and the patient was weaned from cardio-
pulmonary bypass. After the operation, all patients received an inferior
vena caval filter positioned during fluoroscopy.
Medical Treatment
Patients treated medically were treated with a combination of enoxaprin
(fractionated heparin; Lovenox; Sanofi–Aventis, St Louis, Mo), unfrac-
tioned heparin, and warfarin. Recombinant tissue plasminogen activator
and alteplase were the 2 thrombolytics used. Patients treated surgically
were treated with a combination of heparin (unfractioned) and warfarin.
Statistical Analysis
The data are expressed as medians and ranges or percentages. For con-
tinuous variables, a Mann–Whitney test was used. A 2-tailed Fischer’s ex-
act test was used for categorical variables. Long-term survival rates were
calculated with the Kaplan–Meier method. We used the STATA 9. for
Windows statistical software package (StataCorp, College Station, Tex).gery c December 2011
FIGURE 2. Contrast-enhanced chest computed tomographic scan (axial
section) showing a large embolus (type B).
Greelish et al Acquired Cardiovascular DiseaseRESULTS
Of the 103 patients with type A PE, 15 (14%) were
treated with immediate surgical pulmonary embolectomy,
and 88 (85%) were treated medically. Preoperative pa-FIGURE 3. Algorithm for diagnosis a
The Journal of Thoracic and Cartients’ demographics and risk factors for deep venous
thrombosis (DVT) and PE are shown in Tables 1 and 2.
Surgical patients were more likely to be male (86.7% vs
63.1%, P ¼ .046), have a greater body mass index (31 vs
29 kg/m2, P ¼ .027), and have a higher baseline
creatinine value (1.2 vs 1.0 mg/dL, P ¼ .004). Although
symptoms at the time of presentation were also similar
between groups, hemodynamic instability defined as
a systolic blood pressure of less than 90 mm Hg or
requiring intravenous pressors was present in nearly half
(47%) of the surgically treated patients but in only 8% of
the medically treated patients (P ¼ .001, Table 3). Thus
the surgical population was significantly more ill. In the
subgroup of patients who were hemodynamically unstable,
the 30-day mortality was similar for patients treated surgi-
cally versus patients treated medically (29% vs 43%,
P ¼ 1.000).
At follow-up, the overall mortality (both operative and
late) in the medical group was 71% versus 43% in the sur-
gical group (P ¼ .559). Consistent with our treatment algo-
rithm, the most common indication to perform pulmonary
embolectomy was the presence of RV dysfunction on pre-
operative echocardiographic analysis (9/15 [60%]). Con-
traindications to thrombolysis were present in only
a minority of patients (4/15 [27%]) because of recent
surgical intervention (n ¼ 2) and recent trauma (n ¼ 2,
Table 4).nd treatment of pulmonary emboli.
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TABLE 1. Preoperative data for patients with type A pulmonary emboli
Variable Total cohort (n ¼ 103) Surgical (n ¼ 15) Medical (n ¼ 88) P value
Median age (y) 56 (18–97) 57 (25–90) 56 (18–97) .633
Male sex 62 (63.1%) 13 (86.7%) 52 (59.1%) .046
Median BMI (kg/m2) 30 (16–51) 31 (26–49) 29 (16–51) .027
Congestive heart failure 6 (6%) 2 (13%) 4 (5%) .210
Chronic obstructive pulmonary disease 7 (7%) 2 (13%) 5 (6%) .269
Median baseline creatinine (mg/dL) 1.0 (0.3–2.6) 1.2 (0.7–2.6) 0.9 (0.3–1.9) .004
Hypertension 43 (41%) 5 (33%) 37 (42%) .583
Diabetes 19 (18%) 4 (27%) 15 (17%) .470
History of myocardial infarction 1 (1%) 1 (7%) 0 (0%) .146
Previous sternotomy 4 (4%) 0 (0%) 4 (5%) 1.000
BMI, Body mass index.
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tervention underwent preoperative echocardiographic anal-
ysis, and all (100%) had RV dysfunction. Echocardiograms
were performed in a minority of patients treated medically
(35/88 [40%]), but nearly half (47%) had RV dysfunction.
Therefore RV dysfunction was present in the majority (28/
47 [60%]) of patients with type A PE undergoing echocar-
diographic analysis. Echocardiography was performed in
only a small proportion of patients with type B PE (35/
672 [5%]), yet the prevalence of RV dysfunction in those
35 patients was much smaller than in the patients treated
surgically (10% vs 60%, P ¼ .001).
Anticoagulation and inferior vena caval filter strategy also
differed significantly between the medically and surgically
treated groups. The majority of patients with type A PE
treated medically were treated with a combination of enox-
aprin (fractionated heparin, 73/88 [83%]), unfractioned hep-
arin (18/88 [20%]), and warfarin (62/88 [70%]), whereas
less than a third received prophylactic inferior vena cavalTABLE 2. Risk factors for type A PE
Variable Total cohort (n ¼ 103)
BMI>30 kg/m2 (obesity) 48 (47%)
BMI>40 kg/m2 (morbid obesity) 12 (12%)
History of DVT 9 (9%)
Current DVT 33 (32%)
Prior PE 16 (16%)
Smoking history 25 (24%)
Cancer 34 (33%)
Terminal cancer 21 (20%)
Hypercoagulability 8 (8%)
Immobility 22 (21%)
Trauma<1 m 3 (3%)
Major operation<1 m 11 (11%)
History of CVA 6 (6%)
Pregnancy/after delivery 3 (3%)
Estrogen replacement therapy 1 (1%)
Birth control pills
Other 3 (3%)
Not known 3 (3%)
PE, Pulmonary emboli; BMI, body mass index; DVT, deep venous thrombosis; CVA, cere
1426 The Journal of Thoracic and Cardiovascular Surfilter placement (19/88 [21%]). In contrast, surgical patients
were generally treated with heparin (unfractionated, 10/15
[67%]) and warfarin (9/15 [60%]) but not fractionated hep-
arin (0/15 [0%]). Nearly all surgical patients (14/15 [93%])
received inferior vena caval filters (Table 5).
Median cardiopulmonary bypass time was 59 minutes
(range, 21–165 minutes). Two (13%) patients left the oper-
ating roomwith the chest open because of hemodynamic in-
stability. In the postoperative period, 2 (13%) of 15 patients
had low cardiac output syndrome, and one of them required
RV assist device placement. Postoperative renal failure oc-
curred in 2 (13%) patients, and stroke occurred in 1 (7%)
patient. The majority of patients were successfully weaned
from the ventilator without the need for tracheostomy
(93%). There were no reoperations for bleeding.
Despite demonstrating greater comorbidities, with nearly
half the patients being hemodynamically unstable or requir-
ing pressors, the patients with type A PE treated surgically
had similar 30-day mortality (13% vs 17%, P ¼ .532)Surgical (n ¼ 15) Medical (n ¼ 88) P value
9 (60%) 39 (46%) .404
4 (27%) 8 (10%) .082
2 (13%) 7 (8%) .616
2 (13%) 31 (35%) .135
2 (13%) 14 (16%) 1.000
3 (20%) 22 (25%) 1.000
2 (13%) 32 (36%) .135
1 (6%) 20 (22%) .295
1 (7%) 7 (8%) 1.000
4 (27%) 18 (20%) .733
2 (13%) 1 (1%) .055
2 (13%) 9 (10%) .661
0 (0%) 6 (7%) .589
0 (0%) 3 (3%) 1.000
0 (0%) 1 (1%) 1.000
0 (0%) 3 (3%) 1.000
1 (7%) 2 (2%) .380
brovascular accident.
gery c December 2011
TABLE 3. Symptoms at presentation for type A pulmonary emboli
Variable Total cohort (n ¼ 103) Surgical (n ¼ 15) Medical (n ¼ 88) P value
Dyspnea 86 (84%) 15 (100%) 71 (81%) .070
Chest pain 49 (48%) 8 (53%) 41 (47%) .781
Hemoptysis 8 (8%) 0 (0%) 8 (9%) .599
Cough 21 (20%) 2 (13%) 19 (22%) .730
Tachycardia, HR>100 beats/min 41 (40%) 8 (53%) 33 (38%) .267
Hemoinstability (SBP<90 mm Hg or requiring pressors) 14 (14%) 7 (47%) 7 (8%) .001
Syncope 12 (12%) 4 (28%) 8 (9%) .072
Cardiac arrest 3 (3%) 1 (7%) 2 (2%) .380
Leg pain/swelling 20 (19%) 1 (7%) 19 (22%) .292
HR, Heart rate; SBP, systolic blood pressure.
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type B PE had an overall 10% (53/672) 30-day mortality.
Notably, the 2 deaths that occurred in the surgically
treated group were both in patients requiring preoperative
cardiopulmonary resuscitation (CPR). The first occurred
in a 90-year-old woman of small stature (body mass index,
26.24 kg/m2) who presented with acute respiratory failure
requiring intubation. She experienced hypotension leading
to pulseless electrical activity arrest and required CPR 3
times before being taken to surgical intervention. A CT
scan of the chest revealed a large saddle embolus occluding
the main pulmonary and primary branch vessels, with an
echocardiogram demonstrating severe RV dysfunction.
Emergency salvage pulmonary embolectomy was per-
formed successfully. However, the patient had multisystem
organ failure in the postoperative period, and care was with-
drawn.
The second death occurred in a 37-year-old morbidly
obese man (331 lbs; body mass index, 43 kg/m2) who pre-
sented with marked hemodynamic instability (blood pres-
sure, 80/52 mm Hg; heart rate, 123 beats/min).
Echocardiographic analysis revealed a massive right atrial
clot extending into the right ventricle and pulmonary trunk.
On transfer to the operating room, he arrested, and CPRwas
initiated with open cardiac message. After being started on
cardiopulmonary bypass, successful pulmonary embolec-
tomy was performed, and hewas transferred to the intensive
care unit. He had severe right-sided heart failure requiringTABLE 4. Indications for surgical embolectomy in patients with type
A PE
Indication No. (n ¼ 15)
Contraindication to thrombolysis 4/15 (27%)
n ¼ 2, hemodynamically unstable
n ¼ 2 with RV dysfunction
Large RA–RV thrombus 2/15 (13%)
n ¼ 1, left renal cell carcinoma with
caval thrombus extending up to
the RA
n ¼ 1, large RA thrombus
RV dysfunction 9/15 (60%)
RA, Right atrium; RV, right ventricle.
The Journal of Thoracic and CarRVassist device placement but went on to have multisystem
organ failure and died on postoperative day 7.
Among the patients treated medically, 17 died within 30
days, and 8 (47%) of 17 had cardiopulmonary failure
caused by PE.
Kaplan–Meier survival analysis (Figure 4) revealed im-
proved long-term outcomes in the surgical group. Mean
follow-up was 24  18 months (range, 1–82 months), and
follow-up was 100% complete. Actuarial survival was
92%  7.4% (95% confidence interval [CI], 0.57% to
0.98%) for patients with type A PE treated surgically at 1
and 3 years versus 74%  5% (95% CI, 0.62% to
0.82%) and 66.6%  6.1% (95% CI, 0.53% to 0.77%)
for patients with type A PE treated medically
(P ¼ .0001), respectively.
Regarding late mortality, the cause of death in the surgi-
cal group was cancer (1 patient), and for the medically
treated group (n ¼ 23), the causes were cancer (14/23
[60%]), cardiac (3/23 [13%]), neurologic (3/23 [13%]), re-
spiratory failure (1/23 [4%]), and ‘‘unknown’’ (3/23
[13%]).DISCUSSION
In this series of patients with a documented large central
clot burden (type A) have similar 30-day mortality with
medical or surgical treatment, despite the latter group being
more hemodynamically unstable and with the presence of
RV dysfunction. All patients in this series and 2 of 3 in
our Boston series3 who required preoperative CPR died.
Had we not operated on the 2 patients who required preop-
erative CPR, the operative mortality in the surgical group
would have been 0%. This suggests that preoperative
CPR might be a contraindication to surgical intervention.
The late survival, however, seems better for patients with
type A PE treated surgically compared with those treated
medically. Thus surgical pulmonary embolectomy should
be considered for patients with documented large central
clot burden (type A) and documented impending RV
failure.
Over the past few decades, there has been a significant
decrease in mortality from cardiovascular disease, thediovascular Surgery c Volume 142, Number 6 1427
TABLE 5. Treatment of type A pulmonary emboli
Variable Total cohort (n ¼ 103) Surgical (n ¼ 15) Medical (n ¼ 88) P value
Inferior vena caval filter 33 (32%) 14 (93%) 19 (21%) .001
Preexisting 4/34 0/14 4/19
In addition to medical/surgical treatment 29/34 14/14 15/19
Enoxaprin (Lovenox) 73 (71%) 0 (0%) 73 (83%) .001
Other heparins 28 (27%) 10 (67%) 18 (20%) .001
Warfarin sodium (Coumadin) 71 (69%) 9 (60%) 62 (70%) .547
Aspirin 21 (20%) 11 (73%) 10 (11%) .001
Clopidogrel (Plavix) 3 (3%) 2 (13%) 1 (1%) .055
Thrombolytics 2 (2%) 2 (2%)*
*Thrombolytics used: 1 patient, alteplase; 1 patient, recombinant tissue plasminogen activator.
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mortality from DVT and PE has remained high (17% at 3
months).4 Current estimates indicate that 350,000 to
600,000 persons per year are given diagnoses of DVT and
PE in the United States, with 100,000 to 180,000 deaths at-
tributed to these causes annually. The significance of the
high mortality associated with this disease has led the US
Surgeon General in 2008 to issue a call to action for the
prevention of DVT and PE to bring national attention to
this issue.5
In a multivariate analysis of a large cohort of patients
(n ¼ 2454) with PE in the International Cooperative Pul-
monary Embolism Registry, RV hypokinesis was found
to be the most significant prognostic factor, doubling the
mortality rate when present.4 During the first 30 days after
PE, acute RV failure accounts for the majority of deaths,
whereas underlying disease is responsible for mortality
thereafter. The right ventricle is a thin-walled structure
with poor ability to adapt to acute changes in afterload.
Proximal clot in the main pulmonary trunk obstructs
flow, induces a pressure load on the right ventricle, and
leads to acute RV distension and eventual failure. This
study categorized patients with proximal pulmonary arteryFIGURE 4. Kaplan–Meier survival curve after surgical pulmonary embo-
lectomy and medical treatment for patients with type A pulmonary emboli.
1428 The Journal of Thoracic and Cardiovascular Surclots as having type A disease, thus creating an anatomic
surrogate for RV dysfunction. Moreover, classifying pa-
tients in this way defines those who have surgically acces-
sible clot and rapidly allows the practitioner to distinguish
patients most likely to benefit from surgical intervention.
The proposed classification system is analogous to that of
the Stanford classification system in aortic dissection in
which patients with type A disease carry the highest
predicted mortality and require surgical intervention,
whereas patients with type B disease can safely be treated
medically.
Analysis of preoperative presentation in our study re-
vealed that nearly half of the patients with type A PE treated
surgically were hemodynamically unstable compared with
only 8% of those treated medically. This finding reflects ad-
herence to more traditional indications to refer to surgical
intervention late and importantly speaks to the higher pre-
dicted mortality in the surgically treated subgroup. Mortal-
ity rates as high as 58% versus 15% have been reported in
hemodynamically unstable versus hemodynamically stable
patients, respectively, in the International Cooperative Pul-
monary Embolism Registry.4 As such, the surgical sub-
group in our study constituted a much sicker population.
Although additional studies are needed, we believe the
success of our treatment protocol stems from its targeting
the major causes of morbidity and mortality in PE, namely
RV failure, recurrent PE, untreated additional clots, and
chronic thromboembolic disease leading to chronic pulmo-
nary hypertension. Surgical pulmonary embolectomy pro-
vides rapid relief of RV dysfunction by means of removal
of clot early in the pathogenic process. As such, RV disten-
sion and strain are minimized. Embolectomy also prevents
clot organization and thromboembolic scarring, lessening
the risk of long-term pulmonary hypertension. Ninety-
three percent of patients treated surgically had intraopera-
tively placed inferior vena caval filters. Although seemingly
an aggressive practice compared with most published
guidelines for inferior vena caval filter placement, large nat-
ural history studies have shown that that nearly half (47%)
of those with recurrent PE (17%) die within 3 months.4,6
Moreover, inferior vena caval filter placement in cases ofgery c December 2011
Greelish et al Acquired Cardiovascular Disease
A
C
Dmassive PE has been shown to reduce recurrent PE and 90-
day mortality.7 Therefore it is our opinion that recurrent PE
remains a significant threat after a massive pulmonary em-
bolism and warrants inferior vena caval filter placement.
Importantly, RV dysfunction at the time of presentation has
been shown tobe themost importantdeterminant of earlymor-
tality in patients with PE.4,8,9 Consequently, echocardiograms
were obtained for the majority of patients treated surgically
(80%), which is consistent with our planned treatment
algorithm. Three patients did not receive preoperative
echocardiographic analysis because their conditions were
unstable, but all of them underwent intraoperative
transesophageal echocardiographic assessment. In contrast,
only 40% of patients in the medically treated group
underwent echocardiographic analysis. RV dysfunction was
found in all surgical patients and 47% of medically treated
patients. Therefore RV failure was present in the majority of
patients with type A PE (surgical and medical) with
echocardiograms. This finding is consistent with our
hypothesis that our anatomic classification system serves as
a surrogate marker for RV dysfunction.
Because of inconsistent treatment algorithms over
a 6-year period, some patients treated medically were sim-
ply never considered for surgical intervention. Currently,
we have a team approach, with surgeons and cardiologists
working together as a team and providing the same algo-
rithm of treatment. Moreover, only 40% of patients in the
medical group received echocardiographic analysis of the
right ventricle. These observations point to the need for
a universally accepted approach to patients presenting
with PE. We believe that all patients with suspected PE
should undergo imaging (CTangiographic imaging) to con-
firm the diagnosis and allow anatomic classification as type
A or type B. In addition, all patients should undergo echo-
cardiographic analysis to assess RV function. Patients with
type A PE should be referred for consideration of surgical
embolectomy because our results have shown that the ma-
jority of these patients (29/47 [62%]) will have significant
RV dysfunction, the main determinant of mortality in the
first 30 days. Expeditious embolectomy in patients with
type A PE with RV dysfunction will subsequently
result in improved long-term survival. We do not recom-
mend catheter embolectomy because of the risk of PE
fragmentation.The Journal of Thoracic and CarLimitations
This is a retrospective review in a relatively small cohort.
Verification of these results in a randomized trial would be
optimal. The type of treatment was based on individual pa-
tient selection. Although not statistically significant, cancer
occurred more frequently in the medically treated patients
than in those treated surgically. Consequently, it is possible
that survival statistics were affected accordingly. Also,
a more aggressive anticoagulation and inferior vena caval
filter strategy was used in the surgical group.
CONCLUSIONS
For type A PE, immediate surgical intervention offers su-
perior long-term survival compared with medical treatment
alone. Immediate surgical embolectomy should be strongly
considered in this group of patients because most have RV
dysfunction, the most important determinant of early mor-
tality. This new classification for PE simplifies decision
making and might help direct optimal treatment strategies.
Other contributing authors included Tarek S. Absi, MD; Ste-
phen K. Ball, MD; Jorge M. Balaguer, MD; Julian S. Bick, MD;
Susan S. Eagle, MD; Pretorius Mias, MD; Robert J. Deegan,
MD; Steven J. Hoff, MD; Michael R. Petracek, MD; and Anne-
Marie Thompson, MD
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